Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer's disease.

Autor: Shi J; Department of Neurology, Institute on Aging and Brain Disorders, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China. Electronic address: jshi2022@ustc.edu.cn., Touchon J; Institute of Neuroscience, University Hospital Gui de Chauliac-Montpellier, Montpellier 34295, France., Middleton LT; Ageing Epidemiology (AGE) Research, School of Public Health, Imperial College, London SW7 2AZ, UK., Rovira MB; Centro de Investigación Biomédica en Red sobre, Enfermedades Neurodegenerativas (CIBERNED), Universitat International de Catalunya-Barcelona, Barcelona 08028, Spain., Vassar R; Department of Cell Biology, Medical School, Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA., Vellas B; IHU HealthAge, WHO Collaborating Center for Frailty, Clinical & Geoscience Research and Geriatric Training, Toulouse University Hospital, INSERM UMR 1295, University Paul Sabatier, Toulouse 31000, France. Electronic address: vellas.b@chu-toulouse.fr., Shen Y; Department of Neurology, Institute on Aging and Brain Disorders, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China. Electronic address: yongshen@ustc.edu.cn.
Jazyk: angličtina
Zdroj: Science bulletin [Sci Bull (Beijing)] 2024 Dec 15; Vol. 69 (23), pp. 3777-3784. Date of Electronic Publication: 2024 Sep 28.
DOI: 10.1016/j.scib.2024.09.042
Abstrakt: After a number of failed drug studies on Alzheimer's disease (AD) over the past decade, clinical trials of AD started to show encouraging results and were approved or pending approval for clinical use. However, controversies on the clinically meaningful benefits and risks of brain edema and microhemorrhages have reminded us to think further about monitoring treatment and developing new drug targets. The goal of this review is to find insights from clinical trials that aimed at two key pathological features of AD, i.e., amyloid-β (Aβ) and tau protein, and to explore other targets such as anti-inflammation in AD. The complex pathophysiology of AD may require combination therapies rather than monotherapy. Throughout the course of AD, multiple pathways are disrupted, presenting a multitude of possible therapeutic targets for designing prevention and intervention for AD.
(Copyright © 2024 Science China Press. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: